| Initiated | Buy | X | ||
| Initiated | Buy | X | ||
| Initiated | Overweight | X | ||
| Resumed | Buy | X | ||
| Initiated | Buy | X | ||
| Resumed | Underweight | X | ||
| Upgrades | Mkt Perform Outperform | X | ||
| Upgrades | Underperform Hold | X | ||
|
$1.50 $1 |
||||
| Downgrades | Hold Underperform | X | ||
|
$3.20 $1.50 |
||||
| Downgrades | Neutral Underweight | X | ||
| Resumed | Hold | X | ||
|
$12 $4 |
||||
| Downgrades | Neutral Sell | X | ||
| Downgrades | Outperform Mkt Perform | X | ||
| Downgrades | Buy Neutral | X | ||
|
$35 $8 |
||||
| Downgrades | Neutral Underperform | X | ||
|
$18 $6 |
||||
| Downgrades | Buy Neutral | X | ||
| Downgrades | Buy Hold | X | ||
|
$24 $5 |
||||
| Downgrades | Outperform Mkt Perform | X | ||
| Upgrades | Perform Outperform | X | ||
| Upgrades | Hold Buy | X | ||
| Upgrades | Hold Buy | X | ||
|
$22 $24 |
||||
| Resumed | Neutral | X | ||
| Downgrades | Buy Hold | X | ||
| Initiated | Hold | X | ||
| Downgrades | Buy Hold | X | ||
|
$59 $23 |
||||
| Downgrades | Overweight Neutral | X | ||
|
$62 $33 |
||||
| Downgrades | Buy Neutral | X | ||
|
$79 $21 |
||||
| Initiated | Mkt Perform | X | ||
| Initiated | Buy | X | ||
| Downgrades | Buy Neutral | X | ||
| Reiterated | Buy | X | ||
|
$125 $97 |
||||
| Initiated | Buy | X | ||
| Resumed | Overweight | X | ||
| Reiterated | Buy | X | ||
|
$89 $103 |
||||
| Resumed | Buy | X | ||
| Reiterated | Buy | X | ||
|
$80 $94 |
||||
NKTR Nektar Therapeutics
Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.
